NautaDutilh advises Vivoryon Therapeutics in its EUR 25 million private placement
NautaDutilh assisted Vivoryon Therapeutics a clinical stage company focused on the discovery and development of small molecule medicines in successfully raising EUR 25 million through an accelerated bookbuild offering (ABB).
In the offering Vivoryon issued new shares representing approximately 7.4% of Vivoryon’s existing issued share capital, which will be listed and traded on Euronext Amsterdam.
Vivoryon’s lead product candidate, varoglutamstat is a small molecule medicine in development for the treatment of Alzheimer’s disease.
Antonia Netiv, Capital Markets partner, commented: "It was a pleasure to assist Vivoryon in its successful EUR 25 million capital raise. Vivoryon is a truly inspiring company and a great team to work with.”
